These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31633213)

  • 1. "I live, I don't work, but I live a very normal life"-A qualitative interview study of Scandinavian user experiences of schizophrenia, antipsychotic medication, and personal recovery processes.
    Møllerhøj J; Os Stølan L; Erdner A; Hedberg B; Stahl K; Riise J; Jedenius E; Rise MB
    Perspect Psychiatr Care; 2020 Apr; 56(2):371-378. PubMed ID: 31633213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic.
    Lai JK; Margolese HC
    Schizophr Res; 2019 Feb; 204():443-444. PubMed ID: 30241989
    [No Abstract]   [Full Text] [Related]  

  • 3. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.
    Arteaga Duarte CH; Fakra E; Van Gils C; Guillon P
    Encephale; 2019 Dec; 45(6):459-467. PubMed ID: 31542210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate - a qualitative interview study.
    Rise MB; Stølan LO; Erdner A; Hedberg B; Stahl K; Riise J; Jedenius E; Møllerhøj J
    Nord J Psychiatry; 2021 May; 75(4):257-265. PubMed ID: 33151121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
    Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
    J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medication Adherence, Side Effects, and Quality of Life.
    Sağlam Aykut D
    J Clin Psychopharmacol; 2019; 39(1):57-62. PubMed ID: 30566417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia.
    Bell Lynum KS; Turkoz I; Kim E
    Early Interv Psychiatry; 2019 Jun; 13(3):667-672. PubMed ID: 29968279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
    Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
    Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
    Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
    J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans.
    Emond B; El Khoury AC; Patel C; Pilon D; Morrison L; Zhdanava M; Lefebvre P; Tandon N; Joshi K
    Curr Med Res Opin; 2019 Mar; 35(3):407-416. PubMed ID: 30556739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
    Morris MT; Tarpada SP
    Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery.
    Williams W; McKinney C; Martinez L; Benson C
    J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia.
    Rossenu S; Cleton A; Hough D; Crauwels H; Vandebosch A; Berwaerts J; Eerdekens M; Herben V; De Meulder M; Remmerie B; Francetic I
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):270-8. PubMed ID: 27136907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans.
    DerSarkissian M; Lefebvre P; Joshi K; Brown B; Lafeuille MH; Bhak RH; Hellstern M; Bobbili P; Shiner B; El Khoury AC; Young-Xu Y
    Clin Ther; 2018 Sep; 40(9):1496-1508. PubMed ID: 30145029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia.
    Hargarter L; Lahaye M; Cherubin P; Lambert M; Swarz M; Joldygulov G; Vischia F; Chomskaya V; Bozikas VP; Tsapakis EM; Schreiner A
    World J Biol Psychiatry; 2018; 19(sup3):S147-S157. PubMed ID: 28594264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort.
    Martínez-Andrés JA; García-Carmona JA
    Schizophr Res; 2019 Oct; 212():234-236. PubMed ID: 31421972
    [No Abstract]   [Full Text] [Related]  

  • 18. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
    Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
    Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate.
    Kern Sliwa J; Savitz A; Nuamah I; Mathews M; Gopal S; Elefant E; Najarian D; Alphs L
    Perspect Psychiatr Care; 2018 Oct; 54(4):530-538. PubMed ID: 29446084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Concentration of Paliperidone Palmitate Administered Every 3 Weeks.
    Cohen JY; Dumoulin-Charette A; Meraabi N; Poirier R
    Psychopharmacol Bull; 2019 Jun; 49(2):57-62. PubMed ID: 31308584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.